Author: Editor

Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health discusses, How To Manage 2nd And 3rd Line mCRC Patients. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Whether Regorafenib Is Becoming More Tolerable For mCRC Patients. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Genetic Testing In Newly Diagnosed mCRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Thoughts On Checkpoint Inhibitors In Adjuvant CRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Managing 2nd And 3rd Line mCRC Patients. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, BEACON Study In BRAF Mutated Metastatic Colorectal Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Nevena Damjanov, MD, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses, The Impact Of The ReDOS study In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Nevena Damjanov, MD, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses, Sequencing TKIs In Hepatocellular Carcinoma (HCC). At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Nevena Damjanov, MD, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses, Thoughts On The Role Of Systemic Therapy In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Nevena Damjanov, MD, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses, Stereotactic Body Radiation Therapy In Early Stage HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Discusses Screening Patients At High Risk For Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Discusses Opinion On NGS And BRCA Gene Testing In Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Discusses Neoadjuvant Chemotherapy & Upfront Surgery In Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Discusses Promising Novel Therapies For Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Discusses Molecular SubTyping Of Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses The Use Of Regorafenib In The Management Of Advanced CRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses Patient Selection & Treatment Algorithms In 2nd And 3rd Line CRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses The Role Of Circulating Tumor DNA (ctDNA). At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses CCTG CO.26 Trial In Advanced Refractory CRC Presented At GI 2019. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses Next Generation Sequencing And mCRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, Discusses The Latest In Identifying Valid Biomarkers In The Treatment Of HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019.

Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, Discusses Key Takeaways From GI 2019 Regarding The Treatment Of Biliary Tract Cancers. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019.

Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, Discusses Next Generation Sequencing And mCRC Treatment. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019.

Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, Discusses Is ctDNA Is A Valid Treatment Response In CRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019.

David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses Pembrolizumab & Chemotherapy In Advanced Esophageal Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses Results From The TAGS Trial Presented At GI 2019. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, discusses Targeted Therapies In The Treatment Of Cholangiocarcinoma. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, discusses How BRAF Mutations Figure Into Cholangiocarcinoma Treatment. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, discusses The Utilization Of TKIs In Treatment Of Hepatocellular Carcinoma. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, discusses Pre-Operative Therapy In Resectable Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Andrew X. Zhu, MD, PhD Associate Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, Discusses What Physicians Should Know About Sequencing TKIs In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Andrew X. Zhu, MD, PhD Associate Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, Discusses Checkpoint Inhibitors In Advanced HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Andrew X. Zhu, MD, PhD Associate Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, Discusses Considering Whether Sorafenib Is Tolerable In Combination With I-O In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses Targeted Therapies In Treatment Of Cholangiocarcinoma. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses The Role Of BRAF Mutations In Treatment Of Cholangiocarcinoma. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses How We Can Utilize TKIs In The Management Of Hepatocellular Carcinoma. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses The Use Of Regorafenib In Treatment Of Colorectal Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Finn, MD Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA discusses Combined Checkpoint Inhibition In HCC & Biliary Tract Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Finn, MD Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA discusses Thoughts On The Role Of Systemic Therapy In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the use of stereotactic radiosurgery and stereotactic radiation therapy.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation therapy for inoperable lung lesions.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.

Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Protein Biomarkers, PD-L1, & Multifactorial. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Is The Secreted Variant Of PD-L1 A Systemic Immunosuppressant. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Data Regarding A Splice Variant Of PD-L1. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses Which Patient For Which Treatment. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses Over-Diagnosis & Over-Treatment Of Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses Increasing Awareness In Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses How To Better Treat Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Abhishek Tripathi, M.D. Assistant Professor Of Medicine In The Section Of Hematology/Oncology At Oklahoma Stephenson Cancer Center Discusses Adenosine Pathway Inhibitors In Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Steven Raman, M.D. Director of Prostate MR Imaging and Interventions and UCLA Prostate MR Imaging Research Group Discusses, MRPET & The Future Of Imaging. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, More Trials & Drugs Coming In 2019. At MOASC on Jan 19, 2019.

Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, How MAIA & FORTE Trials Effect Clinicians. At MOASC on Jan 19, 2019.

Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, Highlights Of MAIA, FORTE & Tourmaline MM-3 Trials. At MOASC on Jan 19, 2019.

Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses Data On The ALLIANCE Trial. At MOASC on Jan 19, 2019.

Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Low MRD. At MOASC on Jan 19, 2019.

Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Its Effect On Clinicians. At MOASC on Jan 19, 2019.

Tianyi Tang, M.D. Hematology/Oncology Fellow At University of California, Irvine Discusses How The MAIA Trial Will Effect Clinicians . At MOASC on Jan 19, 2019.

Tianyi Tang, M.D. Hematology/Oncology Fellow At University of California, Irvine Discusses Highlights Of The MAIA Trial. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses Ruxolitinib Study & Communication. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses Where Should AYA Patients Be Treated. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses Improving The Treatment Of AYA Patients. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses Clinical Trial Enrollment & ALL Mutations in AYA. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses AYA Cancer Research & The Future. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses Adolescent & Young Adult Oncology. At MOASC on Jan 19, 2019.

Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Where We Are In Our Understanding Of DLBCL. At MOASC on Jan 19, 2019.

Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Whats Next In DLBCL. At MOASC on Jan 19, 2019.

Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Next Steps In R-CHOP Studies. At MOASC on Jan 19, 2019.

Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Two Abstracts That Could Effect Clinicians. At MOASC on Jan 19, 2019.

Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Four Abstracts Presented At MOASC. At MOASC on Jan 19, 2019.

Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Newer Agents Coming Out For TTP. At MOASC on Jan 19, 2019.

Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Updates On Thrombotic Microangiopathies. At MOASC on Jan 19, 2019.

Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Atypical Hemolytic Uremic Syndrome. At MOASC on Jan 19, 2019.

Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Data On TITAN Study & HERCULES Trial. At MOASC on Jan 19, 2019.

Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Three New Drugs Approved For AML. At MOASC on Jan 19, 2019.

Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Dosing Regarding Venetoclax. At MOASC on Jan 19, 2019.

Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Can Glasdegib Be Used As A Single Agent. At MOASC on Jan 19, 2019.

Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers, Discusses PEDIGREE Trial & The Role It Plays In Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers, Discusses PEDIGREE Trial Coming Early 2019. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers, Discusses Discussing JAVELIN Renal 101 & KEYNOTE-426 Data. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers, Discusses Data On PEDIGREE Trial For Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers, Discusses CheckMate 214 Data Presentation. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Samra Turajlic, M.D. Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Discusses What To Achieve With The TRACERx Renal Study. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Samra Turajlic, M.D. Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Discusses Results From TRACERx Renal Study. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Samra Turajlic, M.D. Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Discusses The TRACERx Renal Study. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Tumor Enucleation Debate. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Overview of Sessions From KCA Miami. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Tumor Enucleation. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Benefits Of Tumor Enucleation. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Sumantra Kumar Pal, M.D. Assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope, Discusses What Therapies Are To Come. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Sumantra Kumar Pal, M.D. Assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope, Discusses Implementation Of Targeted Therapies In Front Line Setting. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses VEGF Plus Radium 223 Study Efficacy. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses Treating Patients With Bone Metastases. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses Study Involving VEGF-Targeted Therapy With Radium 223. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Upcoming Data Coming In 2019. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Profiling Tumor Microenvironment. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Next Gen Immune Activation In Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Figuring Out Best Drug Combo For Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Discussing Combining Drugs In Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Alexander Kutikov, M.D. Chief, Division of Urology and Urologic Oncology Professor At Fox Chase Cancer Center, Department of Surgical Oncology Kidney, Bladder, and Prostate Cancer TRDG Member, discusses Next Step In Tumor Resection. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Alexander Kutikov, M.D. Chief, Division of Urology and Urologic Oncology Professor At Fox Chase Cancer Center, Department of Surgical Oncology Kidney, Bladder, and Prostate Cancer TRDG Member, discusses Debate On Tumor Enucleation. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Making Immunotherapy Work Better For Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Can A Rituximab Biosimilar Replace Rituximab. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses GRIFFIN Trial Safety & Efficacy. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses Treatment Of T-Cell Compared To B-Cell Lymphoma. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Elizabeth Budde, MD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses CAR-T Therapy FDA Approvals. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Edward Copelan, MD, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses Molecular Profiling Of Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Exciting Studies From ASH 2018 Regarding The Treatment Of PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses ECHELON-2 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, discusses Research & Development Philosophy At Janssen. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses Clinical Studies Examining Axicabtagene Ciloleucel. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Samer Khaled, MD, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses MEDALIST Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Samer Khaled, MD, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses Incorporating Venetoclax Into Treatment Regimens For AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Potential Side Effects From Venetoclax + Rituximab In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses MRD As A Surrogate Marker In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, Discusses Clinical Data That Could Change The Way MM Is Treated. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Molecular Testing & AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Current Maintenance Regimens For MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rafael Fonseca, MD, Hematologist, Mayo Clinic, discusses Frontline MM Treatment Patterns. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rafael Fonseca, MD, Hematologist, Mayo Clinic, discusses TOURMALINE-MM3 Study In MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses POLLUX & CASTOR Studies Regarding The Use Of Daratumumab. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses Outcomes Of The CA204-142 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Beat AML Umbrella Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Gilteritinib In AML Treatment. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses Phase 3 Study Investigating Ibrutinib In Older CLL Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses Outcomes Of CAPTIVATE Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope, discusses Standard Of Care In Treatment Of PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope, discusses Successful Induction Regimens When Treating PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Frederick Locke, MD, Program Co-Leader, Immunology Moffitt Cancer Center, discusses Improvements To Turn Around Time With CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Frederick Locke, MD, Program Co-Leader, Immunology Moffitt Cancer Center, discusses How To Integrate CAR-T With Stem Cell Transplant. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses Skepticism Regarding MACRA. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses Key Factors Contributing To Physician Burnout. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Outcomes Of The illUMINTATE Trial. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, Discusses The Use Of Axi-Cel CAR-T Cell Therapy In DLBCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses Checkpoint Inhibitors In Hematologic Malignancies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, Discusses The Role Of Checkpoint Inhibitors In Treatment Of MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Proteasome Inhibitors In The Treatment Of MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Elizabeth Budde, MD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses The Clinical Study Investigating Mosunetuzumab. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com       car t cell therapy,  city of hope, mosunetuzumab

Julie Vose, MD, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Julie Vose, MD, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, Discusses Improvements Made In The Delivery Of CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses Most Exciting Studies In Lymphoma. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses Responses & Outcomes When Treating Lymphoma With CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses The POLLUX & CASTOR Clinical Studies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Improvements In The Treatment Of CTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses The Rationale For Genetically Profiling AML Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Testing For Minimal Residual Disease In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University, Discusses Phase I Study Of Gilteritinib. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Reliability Of The Companion Diagnostic Test For FLT3. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, Discusses Improvements In The Treatment Of CTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andrzej Jakubowiak, MD, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, discusses Thoughts On The POLLUX & CASTOR Studies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andrzej Jakubowiak, MD, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, discusses ALCYONE Trial. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Reliability Of The Companion Diagnostic Test For FLT3. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Molecular Testing In AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

David Siegel, MD, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, discusses TOURMALINE-MM3 Study And The Treatment Of MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

David Siegel, MD, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, discusses Thoughts On The Daratumamab Studies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Incorporation Of Venetoclax Into AML Treatment. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, Discusses Phase 3 Study Investigating Ibrutinib In Younger CLL Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Lorenz Trumper, MD, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses The Current Standard Of Care For The Frontline Treatment Of PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Lorenz Trumper, MD, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses What Differeniates Brentuximab Vedotin From Other Treatment Options. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Maria-Victoria Mateos, MD, Associate Professor of Medicine, University of Salamanca, discusses TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Anti-BCMA CAR-T Cell Therapy In MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses How The FLT3 Mutation Influences Treatment Decisions In AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses Rituximab Biosimilars In Follicular Lymphoma. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses Outcomes Of The ECHELON-2 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Emerging Therapies For Newly Diagnosed Or Relapsed AML Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Maria-Victoria Mateos, MD, Associate Professor of Medicine, University of Salamanca, discusses Outcomes From The ALCYONE Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, discusses The Development Of LCAR-B38M. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Outcomes Of The ECHELON-2 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses The Use Of Axicabtagene Ciloleucel With Elderly Lymphoma Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Treating CLL Patients With Venetoclax And Rituximab. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Venetoclax In Treatment Of AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses Immunotherapy And The Treatment Of Hematologic Malignancies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses The Impact Of The New Induction Regimen In PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses The Role Of Advanced Practice Practitioners. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

David Siegel, MD, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, discusses Anti-BCMA CAR-T Cell Therapy For MM Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Julie Vose, MD Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Management Of Common Toxicities With CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rafael Fonseca, MD Hematologist, Mayo Clinic, discusses Effectiveness Of Anti-BCMA CAR-T Cell Therapy. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rafael Fonseca, MD Hematologist, Mayo Clinic, discusses Outcomes Of The POLLUX And CASTOR Studies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Nikhil Munshi, MD Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

James McClosky, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Using Newly FDA Approved Gilteritinib For Patients With AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sundar Jagannath, MD Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Outcomes Of CA204-142 In MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

John Burke, MD Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Reliability Of The FLT3 Mutation Test. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center, discusses Will CAR-T Therapies Be Expanded Into Solid Tumors. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Carol Moreno, MD, PhD Hematologist, University of Barcelona, discusses Outcomes From The iLLUMINATE Trial. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses Real-World Experience Using axi-cel CAR-T Cell Therapy. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Peter Vorhees, MD Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses What Regimens Are Being Used For MM Patients Today. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Ravi Vij, MD Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Nizar Bahlis, MD University of Calgary, Calgary, discusses The Future Of Anti-BCMA CAR-T Cell Therapy In MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Nizar Bahlis, MD University of Calgary, Calgary, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Nizar Bahlis, MD University of Calgary, Calgary, discusses Current Maintenance Regimens For MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Samer Khaled, MD Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses Study Examining The Use Of CAR-T Therapy In ALL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Current Maintenance Regimens In MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses How Gilteritinib Fits Into Treatment Algorithms For AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses Novel Treatment Research Regarding Transplants At City Of Hope. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

James McCloskey, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses The Role Of Molecular Testing In AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Chadi Nabhan, MD, MBA VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses What Is Being Done To Prevent Oncologist Burnout. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses Large B-Cell Lymphoma & How CAR-T Therapies Are Integrated. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Elizabeth Budde, MD Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses How City Of Hope Has Overcome Logistical Hurdles Associated With CAR-T. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jeff Sharman, MD Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses The CLL-14 Studies Importance In Determining CLL Treatment Strategies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Julie Vose, MD Professor Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Does Polatuzumab Improve Outcomes In DLBCL Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Maria-Victoria Mateos, MD Associate Professor of Medicine, University of Salamanca, discusses Addition Of Daratumumab To Revlimid/Dexamethasone In MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rod A. Humerickhouse, MD, PhD Group Project Leader, Oncology Development, AbbVie, discusses Recent Advancements In The Treatment Of CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sen Zhuang, MD, PhD VP, Oncology Clinical Research, Janssen, discusses How LCAR-838M May Impact The Treatment Of MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sattva Neelapu, MD Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses The Future Of CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Lorenz Trumper, MD Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses Results Of The ECHELON-2 Trial. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Outcomes Of The POLLUX And CASTOR Studies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Swaminathan P. Iyer, MD Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses Studies Regarding The Treatment Of PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center, discusses Management Of Toxicity With CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Edward Copelan, MD Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses The Role Of Allogeneic Transplantation In Lymphoma & MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andrew Pecora, MD Chief Innovation Officer, Professor and Vice President of Cancer Services, John Theurer Cancer Center, discusses Results Of The CPIT Trial. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andrzej Jakubowiak, MD Professor of Medicine Director, Myeloma Program University of Chicago Medical Center, discusses GRIFFIN Study Outcomes. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Carol Moreno, MD, PhD Hematologist, University of Barcelona, discusses Recent Advancements In The Treatment Of CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Habte Yimer, MD Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses Discussing The POLLUX And CASTOR Studies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Habte Yimer, MD Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses The Future Of Anti-BCMA CAR-T Cell Therapy. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Habte Yimer, MD Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses Outcomes Of The GRIFFIN Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jason Butler, PhD Associate Scientist, Regenerative Medicine and Associate Professor, ?Center for Discovery and Innovation, Hackensack University, discusses Age-Associated Aberrant MAPK Signaling & How It Impacts Hematopoiesis. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rena Feinman, PhD Associate Scientist, Department of Research, John Theurer Cancer Center at Hackensack University Medical Center, discusses The Role Of The Gut Microbiome In Cancer. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Maria-Victoria Mateos, MD Associate Professor of Medicine, University of Salamanca, discusses Discussing The CASTOR Trial Presented At ASH 2018. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sundar Jagannath, MD Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Maintenance Regimens For Multiple Myeloma Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Tatyana Feldman, MD Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses The Unmet Needs In Peripheral T-cell Lymphoma (PTCL). At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Yana Pikman, M.D. Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Childrens Hospital, Discusses The LEAP Consortium Research Outcomes. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Samer Khaled, MD Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Discusses Treatment Of Acute Myelogenous Leukemia With Gilteritinib. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Robert Rifkin, MD Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers Discusses Does Anti-BCMA CAR-T Cell Therapy Look Promising. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Lorenz Trumper, MD Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen discusses Differences Between B-Cell and T-Cell Lymphomas. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Julie Vose, MD Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center discusses Are CAR-T Therapies Showing Impressive Results In Lymphoma. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andrew Pecora, MD Chief Innovation Officer, Professor and Vice President of Cancer Services John Theurer Cancer Center Discusses The Necessity Of Allogeneic Transplants To MML Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Swaminathan Padmanabhan Iyer, MD Professor, Department of Lymphoma and Myeloma, MD Anderson Cancer Center discusses Game Changing ECHELON-2 Study For Patients With PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center Discusses Using CAR-T Therapies In Leukemia & Lymphoma. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

David Siegel, MD Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center Discusses Results Of MM014 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions Discusses Two Sided Payment Agreements & The Risks Involved. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andrzej Jakubowiak, MD, PhD Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center discusses Multiple Myeloma Maintenance Regimens. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center Discusses Long-Term Outcome Of Acalabrutinib In MCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Ravi Vij, MD Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine Discusses Data Regarding His Clinical Trial Presented At ASH 2018. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Elizabeth Budde, MD Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Discusses CAR-T Therapies In Lymphoma Treatment Algorithms. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

John Burke, MD Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers Discusses Research Examining Gilteritinib In Newly Diagnosed AML At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Nikhil Munshi, MD Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School Discusses How ID2 Function Impacts Oncogenesis In MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

James McCloskey, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center Discusses Application Of The FLT3 Test In Newly Diagnosed AML Patients At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sattva Neelapu, MD Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center Discusses ZUMA-1 Two-Year Follow-Up Study In DLBCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rafael Fonseca, MD Hematologist, Mayo Clinic Discusses Maintenance Regimens For MM At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Discusses AML Genetic Testing Prior To Start Of Therapy. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Peter Vorhees, MD Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute Discusses Outcomes Of The ALCYONE Trial In MM Patients At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Katja Weisel, MD Head of the Myeloma Center, University of Tubingen Discusses Anti-BCMA CAR-T Cell Therapy In MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Edward Copelan, MD Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute Discusses Gilteritinib For Patients With FLT3+ AML At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rena Feinman, PhD Associate Scientist, Department of Research, John Theurer Cancer Center at Hackensack University Medical Center Discusses The Microboime Role In Cancer. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Habte Yimer, MD, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology Discusses Lyra Trial In Newly Diagnosed MM At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, Discusses LCAR-838M Study In Relapsed/Refractory MM At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com